Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Flavoxate hydrochloride

🥰Excellent
Catalog No. T0703Cas No. 3717-88-2
Alias Rec-7-0040, NSC-114649, Flavoxate HCl, DW61

Flavoxate hydrochloride (DW61) , a muscarinic AChR antagonist, is used in the therapy of various urinary syndromes and as an antispasmodic.

Flavoxate hydrochloride

Flavoxate hydrochloride

🥰Excellent
Purity: 99.64%
Catalog No. T0703Alias Rec-7-0040, NSC-114649, Flavoxate HCl, DW61Cas No. 3717-88-2
Flavoxate hydrochloride (DW61) , a muscarinic AChR antagonist, is used in the therapy of various urinary syndromes and as an antispasmodic.
Pack SizePriceAvailabilityQuantity
25 mg$30In Stock
50 mg$43In Stock
100 mg$58In Stock
200 mg$63In Stock
1 g$89In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Flavoxate hydrochloride"

Select Batch
Purity:99.64%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Flavoxate hydrochloride (DW61) , a muscarinic AChR antagonist, is used in the therapy of various urinary syndromes and as an antispasmodic.
Targets&IC50
mAChR:12.2 μM
In vitro
Without altering basal bladder pressure in rats, Flavoxate (3 mg/kg) can halt efferent nerve activity and associated bladder contractions for approximately 10 minutes. At the same dosage, administered intravenously, Flavoxate abolishes rhythmic bladder contractions, with maximum intervals of voiding contractions reaching 7.20 minutes. In rats, at a higher concentration (10 mg/kg), Flavoxate suppresses both the initial rapid-rise contraction phase (Phase 1) and the sustained contraction phase (Phase 2) to an equivalent degree. Furthermore, at this concentration, Flavoxate eliminates bladder contractions without altering contraction amplitude. Intracerebroventricular (ICV) injections of Flavoxate ranging from 50 to 200 mg or intrathecal (IT) injections of 100 to 200 mg dose-dependently abolish rhythmic bladder contractions within 5 to 15 minutes post-administration.
In vivo
Flavoxate inhibits cAMP formation in a concentration-dependent manner (0.01~10 μM) from membranes extracted from the rat cerebral cortex and striatum, an effect completely negated by pertussis toxin pretreatment. At concentrations greater than 10 μM, Flavoxate suppresses detrusor muscle contraction induced by acetylcholine, with a pD value of 4.55, and also inhibits contractions induced by Ca2+, with a pIC50 value of 4.92. Flavoxate concentration-dependently reduces K+-induced contractions of human bladder. It can displace [3H]nitrendipine at Ca2+ channel binding sites, with an IC50 of 254 μM. Flavoxate also concentration- and voltage-dependently inhibits the peak amplitude of inward Ba2+ currents sensitive to the voltage-dependent nifedipine in human detrusor smooth muscle cells (Ki: 10 μM), and inhibits the same Ba2+ currents at both 30°C (Ki = 5.1 mM) and 37°C (Ki = 4.6 mM).
AliasRec-7-0040, NSC-114649, Flavoxate HCl, DW61
Chemical Properties
Molecular Weight427.92
FormulaC24H26ClNO4
Cas No.3717-88-2
SmilesCl.Cc1c(oc2c(cccc2C(=O)OCCN2CCCCC2)c1=O)c1ccccc1
Relative Density.1.203g/cm3
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 1 mg/mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Flavoxate hydrochloride | purchase Flavoxate hydrochloride | Flavoxate hydrochloride cost | order Flavoxate hydrochloride | Flavoxate hydrochloride chemical structure | Flavoxate hydrochloride in vivo | Flavoxate hydrochloride in vitro | Flavoxate hydrochloride formula | Flavoxate hydrochloride molecular weight